ACE inhibitors and diabetics with albuminuria

Marre, Michel; Lièvre, Michel; Châtellier, Gilles; Plouin, Pierre‐François; Wills, C.J.; Keir, Sarah

doi:10.1016/s0140-6736(95)91976-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 After this report, many clinical studies have shown that ACEIs preserve renal function in diabetic nephropathy. 7,[10][11][12] Now, ACEIs are recognized as drugs which demonstrate organ protective actions mediated by not only ACE inhibition but also other various mechanisms.…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension

Okamura

Ogawa

Ito

2011

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are one of the renin angiotensin system (RAS) inhibitors widely used for the treatment of hypertension. Recently, Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) meta-analysis showed that ACEIs had the blood pressure independent beneficial effects on coronary heart events. In this review, we summarized our current knowledge about ACEIs especially imidapril and re-evaluated ACEIs among other RAS inhibitors (RASIs) because ACEIs have wide ranges of beneficial effects in addition to the ACE inhibition which other RASIs do not have such as the up-regulation of bradykinin level, substance P level, the inhibition of matrix metalloproteinase (MMP) activity and stabilization of coronary plaque.

show abstract